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Abstract
Background: Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and
hypercoagulable state, correlations with the incidence of thrombosis remain unclear.
Methods: In this study the upregulation of TF release upon activation of various cancer cell lines, and the
correlation with TF and PAR2 expression and/or activity was examined. Microvesicle release was induced by
PAR2 activation in seventeen cell lines and released microvesicle density, microvesicle-associated TF activity,
and phoshpatidylserine-mediated activity were measured. The time-course for TF release was monitored over
90 min in each cell line. In addition, TF mRNA expression, cellular TF protein and cell-surface TF activities were
quantified. Moreover, the relative expression of PAR2 mRNA and cellular protein were analysed. Any correlations
between the above parameters were examined by determining the Pearson’s correlation coefficients.
Results: TF release as microvesicles peaked between 30–60 min post-activation in the majority of cell lines tested.
The magnitude of the maximal TF release positively correlated with TF mRNA (c = 0.717; p < 0.001) and PAR2 mRNA
(c = 0.770; p < 0.001) expressions while the percentage increase correlated with PAR2 mRNA (c = 0.601; p = 0.011) and
protein (c = 0.714; p < 0.001). There was only a weak correlation between resting TF release, and microvesicle release.
However, TF release in resting cells did not significantly correlate with any of the parameters examined. Furthermore,
TF mRNA expression correlated with PAR2 mRNA expression (c = 0.745; p < 0.001).
Discussion and Conclusions: In conclusion, our data suggest that TF and PAR2 mRNA, and PAR2 protein are better
indicators of the ability of cancer cells to release TF and may constitute more accurate predictors of risk of thrombosis.
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Background
Cancer-related venous thromboembolism (VTE) is the
second most frequent cause of cancer-related mortality
and morbidity associated with many types of cancers. The
hypercoagulable state is detectable in up to 70 % of cancer
patients with a 2–8 fold higher risk of thromboembolism
in cancer patients than normal individuals. VTE itself may
also be an indicator of malignancy. One main cause of the
increased procoagulant activity during malignancy is
the increased expression of tissue factor (TF) by
tumour cells [1, 2]. In the past, analyses of TF in can-
cers have mainly involved the measurement of TF anti-
gen or activity on the surface, or within the cancer cells
[3–7]. A more recent factor associated with the risk of
thrombosis in cancer patients is the release of pro-
coagulant tumour-derived microvesicles into the blood
circulation. These microvesicles can harbour the pro-
tein TF acting as a major inducer of coagulation as well
as containing phosphatidylserine, the presence of which
is essential for the coagulation [8–10]. However, while
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elevated levels of these microvesicles are often associated
with the hypercoagulable state [8–18], there is no clear as-
sociation between the concentration of circulating micro-
vesicles and the incidence of thromboembolism [19–21].
It is known that cells may release microvesicles upon
activation and depending on the stimuli, these microve-
sicles may harbour TF [12, 22–28]. One such factor cap-
able of inducing the release of TF as microvesicles is the
activation of protease activated receptor 2 (PAR2) on the
cell surface [24, 25] which itself, may participate in can-
cer progression [29, 30]. The activation of PAR2 may
occur through the proteolytic activity of coagulation factor
Xa and TF-factor VIIa complex [31]. The exposure of can-
cer cells to these proteases, for example as a consequence
of coming into contact with blood, may therefore prompt
dormant TF-bearing tumour cells to release large quan-
tities of TF-bearing microvesicles. We hypothesise that
the potential of tumour cells to release TF upon activation,
may be a critical criterion in the promotion of hypercoag-
ulable state and precipitation of thrombosis. In this in
vitro study, we have examined this attribute which we
have termed “TF-release potential”, in seventeen different
cells lines, and by correlating this potential to relevant
properties including TF and PAR2 expression, attempted
to identify possible marker which may prove to be indica-
tive of the risk of thrombosis during cancer in vivo.
Methods
Cell lines
Cells lines (ATCC, Teddington, UK) MDA-MB-231, MIA-
Paca-2 and A375 were cultured in DMEM; BxPC-3,
ASPC-1, T-47D, ZR-75-1, WM-266-4 and CorL23 lines
were cultured in RPMI-1640; MCF-7, LS147T, CaCo-2
and SK-MEL-1 cells were cultured in EMEM; HT-29 and
SKOV-3 cells were cultured in McCoy’s 5a medium; NCI-
H209 cells were culture in Iscove medium and LoVo cells
were cultured in Ham’s F-12 K medium. All media were
obtained with Lonza (Cambridge, UK) contained foetal
calf serum 10 % (v/v; Source Bioscience plc, Nottingham,
UK) and MIA-PaCa-2 cells were also supplemented with
1 % (v/v) horse serum (Sigma Chemical Company Ltd.,
Poole, UK).
Microvesicle isolation, analysis and quantification
Cells (2 × 105) were seeded out in 6-well plates and
permitted to adhere. All cells lines were washed and
pre-adapted to respective serum-free medium prior to
activation and harvesting of conditioned media. To in-
duce microvesicle release, the cells were stimulated
with PAR2-activating peptide (PAR2-AP); SLIGRL;
(20 μM) (Sigma). The released cell-derived microvesi-
cles were then isolated from conditioned media and re-
suspended in PBS according to published procedures
[24, 25, 32–34]. The microvesicles were quantified
using the Zymuphen MP assay kit (Hyphen BioMed/
Quadratech Ltd, Epsom, UK) since this attribute was
relevant to the functionality of the microvesicles and
consequently, to this study.
Quantification of TF and PAR2 mRNA expression
Total RNA was isolated using the TRI-reagent system
(Sigma) from 5 × 105 cells. To quantify the amount of TF
mRNA, real-time RT-PCR was carried out in triplicates
using primer sets designed to detect TF and β-actin and
the absolute amounts of TF mRNA quantified as previ-
ously described [35]. Single-step RT-PCR was carried out
in triplicates using 100 ng of total RNA from each sample
tested. A set of previously prepared standard TF mRNA
ranging 0.05-10 ng was included [35]. To assess the ex-
pression of PAR2, real-time RT-PCR was carried out in
triplicates using 100 ng of total RNA from each sample
using primer sets designed to PAR2 and β-actin mRNA.
After the amplification, the ratios of PAR2 mRNA were
determined with respect to that present in MIA-PaCa-2
cells which express low levels of PAR2, using the 2-ΔΔCT
method [36]. The reaction was carried out at an annealing
temperature of 60 °C using the GoTaq® 1-Step RT-qPCR
System (Promega Corporation Ltd, Southampton, UK) on
an iCycler thermal cycler (Bio-Rad, Hemel Hempstead,
UK) and the data analysed. The primers used were:
TF-forward: 5'-TACAGACAGCCCGGTAGAGTG-3',
TF-reverse: 5'-GAGTTCTCCTTCCAGCTCTGC-3',
PAR2-forward: 5'-GAGCCATGTCTATGCCCTGT-3'
PAR2-reverse: 5'-GACACTTCGGCAAAGGAGAG-3'
β-actin-forward: 5'-
TGATGGTGGGCATGGGTCAGA-3',
β-actin-reverse: 5'-GTCGTCCCAGTTGGTGACGAT-3'
Analysis of TF and PAR2 antigen and TF activity
To measure the TF content of the cells, non-activated
cells (5 × 105) were lysed in a non-denaturing lysis buf-
fer (125 μl) containing protease inhibitors (Promega).
The amount of TF protein was then quantified with a
TF-antigen EIA kit (Enzyme Research Laboratories
Ltd, Swansea, UK) using a recombinant full-length TF
(Sekisui Diagnostics/Invitech Ltd, Molesworth, UK) as
previously described [24, 32, 35]. The relative amounts
of cellular PAR2 were assessed by lysing non-activated
cells (5 × 105) in Laemmeli’s buffer (150 μl). The sam-
ples were then separated by 12 % (w/v) SDS-PAGE and
transferred to nitrocellulose membranes at 100 V for
1 h. The membranes were then blocked with TBST
(10 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.05 %
Tween-20) and incubated overnight with a mouse
monoclonal antibody against human PAR2 (SAM11;
Santa Cruz Technology, Heidelberg, Germany) diluted
1:1000 (v/v) in TBST at 4 °C. The membranes were
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then washed with TBST and probed with a goat anti-
mouse horse-radish peroxidase (HRP)-conjugated anti-
body (Santa Cruz) diluted 1:2000 (v/v) for 90 min. The
PAR2 bands were then visualised using the TMB sub-
strate for HRP (Promega) and recorded. The specificity
of the anti-PAR2 antibody was confirmed by using hu-
man dermal endothelial cells as control cells; These
cells exhibit a single band of around 50 kDa when
probed the SAM11 antibody in western blot [37]. As
loading controls, the level of GAPDH was measured
using a goat anti-human GAPDH antibody (V-18;
Santa Cruz) followed by a donkey anti-goat alkaline
phosphatase-conjugated antibody (Santa Cruz) diluted
1:1000 (v/v) and incubated for 90 min. The bands were
then visualised using the Western Blue stabilised alka-
line phosphatase-substrate (Promega) and recorded.
Microvesicle-associated and cell surface (5 × 104) TF
activities were measured using a modified chromo-
genic thrombin-generation assay by inclusion of Tris-
buffered saline (10 mM Tris–HCl pH 7.0, 154 mM
NaCl) as described previously [33]. In addition, the
TF-mediated factor Xa generation and factor VIIa
activity were also measure using the Actichrome TF
activity assay and SPECTROZYME® FVIIa (Sekisui
Diagnostics, Maidstone, UK). To demonstrate that the
thrombin generation was TF-dependent, samples were
pre-incubated with an inhibitory TF monoclonal anti-
body 4509 (Axis-Shield, Dundee, UK) (10 μg/ml) for
1 h prior to the thrombin-generation assay as before
[24, 25, 32]. In addition, to ensure that the thrombin
activation was factor VIIa-dependent, selected reac-
tions were carried out in the presence of factor VIIa-
deficient plasma as previously described [34].
Statistical analysis
All data represent the calculated mean values from the
number of experiments stated in each figure legend ±
the calculated standard error of the mean. Statistical
analysis was carried out using the Statistical Package
for the Social Sciences (SPSS Inc. Chicago, USA). Sta-
tistically significant differences between groups were
assessed by paired t-test. Correlations between the
measured cellular attributes were examined by per-
forming multiple Pearson’s correlation analysis to-
gether with the significance of the values.
Results
The procedure for isolation of the microvesicles was val-
idated previously and the lack of significant amounts of
exosomes shown by measuring the presence of CD9
within the isolated microvesicle samples [33, 34].
Comparison of the expression of TF mRNA and protein in
cell lines
The amount of TF mRNA from cell lines was quanti-
fied using a real-time RT-PCR procedure and the amp-
lification of the standard TF mRNA was shown to be
linear over the range of 0.05-10 ng (not shown) [35].
The basal expression of TF mRNA was highest in LoVo,
ASPC-1, A375 and MDA-MB-231 cell lines, with moder-
ate amounts being expressed in LS174T, SKOV-3, WM-
266-4, NCI-H209, MCF-7 and BxPC-3 cells and low levels
present in the remainder of the cell lines examined
(Fig. 1a). Total cellular TF protein content moderately
correlated (Table 1) with the level of mRNA expression
(Pearson correlation coefficient c = 0.532; p = 0.028) and
in general, cells expressing high levels of TF mRNA in-
cluding LoVo, ASPC-1 and MDA-MB-231 cells also con-
tained high TF antigen levels (Fig. 1b). Exceptions to this
were cell lines such as T47D and CaCo-2 which pro-
duced moderate amounts of TF protein despite low
level mRNA expression, and also cell lines such as
A375 which contained moderate levels of the protein
despite high level expression of TF mRNA. The obser-
vation for the lack correlation between TF mRNA and
TF protein in some of the cell lines tested may arise
from the differing rates of TF mRNA stability in these
cells and may also be significant in the malignant
properties of these cells. However, another mechanism
that alters the correlation between these two measure-
ments is the rate of release of TF from the cells, under
resting conditions since this appears to differ in the
cell lines tested. Furthermore, surface TF activity in
resting cells varied between the cells with LS174T pos-
sessing almost twice as much activity as BxPc-3 cells
(Fig. 1c), but did not correlate with TF mRNA or pro-
tein expression levels (Table 1). The lack of a strong
correlation between TF activity and antigen is not sur-
prising considering that TF activity is strongly altered
by its status and the lipid components of the cell
membrane domains with which TF associates [38–42].
Furthermore, the rate of TF transport and release as
active microvesicles, is also likely to influence the per-
ceived TF activity on the cell surface [35]. Attempts to
measure TF activity using factor Xa generation assay and
factor VIIa enzymatic activity did not produce sufficiently
large differences and the data was abandoned in these
cases.
Comparison of the level of PAR2 mRNA and antigen in
cell lines
Due to the lack of a reliable source of in vitro-transcribed
synthetic PAR2 mRNA, the levels of PAR2 expression
were only measured semi-quantitatively and compared to
that observed in MIA-PaCa-2 cell line which exhibited
very little PAR2 expression. Analysis of PAR2 protein by
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Fig. 1 Quantitative analysis of TF mRNA, protein and surface activity of cell lines. a Total RNA was isolated from each cell lines (5 × 105 cells) and
100 ng used to determine the absolute amount of TF mRNA in each sample using a quantitative real-time RT-PCR. (n = 3) b Cells (5 × 105) were
also lysed and TF protein quantified using a TF-antigen EIA kit. (n = 3) C) Cell surface (5 × 104) TF activities were measured for each cell lines using
a modified chromogenic thrombin-generation assay (n = 3)
Ettelaie et al. Thrombosis Journal  (2016) 14:2 Page 4 of 12
Table 1 Correlations between cell line parameters
TF mRNA TF protein Surface TF activity MV-TF from
resting cells
MV-TF from
activated cells
Increase in
MV-TF activity
PAR2 mRNA PAR2 protein Time-point of
maximalTF release
TF mRNA Pearson Correlation - 0.532* 0.097 0.104 0.717** 0.341 0.745** 0.103 0.342
Significance 0.028 0.710 0.691 0.001 0.181 0.001 0.695 0.179
TF protein Pearson Correlation 0.532* - −0.175 0.094 0.507* 0.441 0.548* 0.341 0.501*
Significance 0.028 0.503 0.720 0.038 0.077 0.023 0.180 0.041
Surface TF activity Pearson Correlation 0.097 −0.175 - 0.209 0.160 −0.196 0.119 0.186 0.391
Significance 0.710 0.503 0.420 0.539 0.451 0.650 0.475 0.121
MV-TF from resting cells Pearson Correlation 0.104 0.094 0.209 - 0.483* −0.453 0.033 −0.238 0.030
Significance 0.691 0.720 0.420 0.050 0.053 0.899 0.358 0.908
MV-TF from activated cells Pearson Correlation 0.717** 0.507* 0.160 0.483* - 0.370 0.770** 0.242 0.484*
Significance 0.001 0.038 0.539 0.050 0.144 <0.001 0.350 0.049
Increase in MV -TF Activity Pearson Correlation 0.341 0.441 −0.196 −0.453 0.370 - 0.601* 0.714** 0.383
Significance 0.181 0.077 0.451 0.053 0.144 0.011 0.001 0.129
PAR2 mRNA Pearson Correlation 0.745** 0.548* 0.119 0.033 0.770** 0.601* - 0.309 0.618*
Significance 0.001 0.023 0.650 0.899 <0.001 0.011 0.227 0.008
PAR2 protein Pearson Correlation 0.103 0.341 0.186 −0.238 0.242 0.714** 0.309 - 0.430
Significance 0.695 0.180 0.475 0.358 0.350 0.001 0.227 0.085
Time-point of maximal TF release Pearson Correlation 0.342 0.501* 0.391 0.030 0.484* 0.383 0.618* 0.430 -
Significance 0.179 0.041 0.121 0.908 0.049 0.129 0.008 0.085
Parameters associated with seventeen cell lines (shown on the table) were determined as shown in Figs. 1–4. Correlations between the measured cellular attributes were examined by performing multiple Pearson’s
correlation analysis (n = 3; * = p < 0.05; ** = p < 0.01)
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western blot indicated the presence of up to 3 bands
which is in line with those indicated on the manufacturer's
site (Santa Cruz Biotechnology) and are thought to arise
from the differential glycosylation of PAR2 protein by dif-
ferent cells [43]. The levels of PAR2 mRNA were highest
in LoVo, ASPC-1 and SKOV-3 cell lines (Fig. 2) while the
levels of PAR2 proteins were elevated in LoVo, SKOV-3,
NCI-H209 and MCF-7 cells lines. The levels of PAR2
mRNA and protein correlated weakly with each other (c
= 0.309; p = 0.227). Relative PAR2 mRNA levels correlated
with TF mRNA expression (c = 0.745; p < 0.001) and pro-
tein levels (c = 0.548; p = 0.023). Neither PAR2 mRNA,
nor protein levels correlated with the cell surface TF
activity.
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Fig. 2 Semi-quantitative analysis of PAR2 mRNA and protein in cell lines. a Total RNA was isolated from each cell lines (5 × 105 cells) and 100 ng
used to determine the relative amount of PAR2 mRNA by real-time RT-PCR using β-actin mRNA as reference. The ratios of PAR2 mRNA were
determined with respect to that expressed by MIA-PaCa-2 cells. (n = 3) b The relative amount of cellular PAR2 was assessed in lysed non-activated
cells (5 × 105) analysed by western blot and probed with an antibody against human PAR2 (SAM11) diluted 1:1000 (v/v) in TBST, developed with
a goat anti-mouse HRP-conjugated antibody and visualised using the TMB substrate. The level of GAPDH was measured using an anti-human
GAPDH antibody (V-18) followed by a donkey anti-goat alkaline phosphatase-conjugated antibody and visualised as above. (n = 3)
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Time course of TF release by the cell lines from
PAR2-activated cells
This study investigated the possibility that the activation
of PAR2 may be a main influence in the ability of cancer
cells to upregulate the procoagulant potential within the
circulation. Moreover, the measurement of TF antigen as-
sociated with microvesicles does not necessarily correlated
with the procoagulant potential of the microvesicles [44].
Consequently, we measured the microvesicle-associated
TF activity rather than TF antigen levels. In order to assess
the time-course of TF release from cells following the acti-
vation, equal numbers of cells (2 × 105) were adapted to
serum-free media and then activated by incubation with
PAR2-AP (20 μM). Conditioned media was collected at
intervals up to 90 min, microvesicles isolated and TF ac-
tivity examined as above. Time-course measurements
were carried out to assess the velocity of cell response and
determine the interval before maximal TF release. How-
ever, since the time-course measurements were carried
out on separate occasions, no comparison of the magni-
tudes between the various cell lines was carried out at this
stage. Therefore, the percentage ratio of TF activity with
respect to time zero has been presented (Fig. 3). The dur-
ation of incubation before achieving maximal TF release
was between 30–60 min in all cell lines except in HT-29
cells in which it was 15 min, and in CaCo-2 cells in which
it was at least 90 min. This speed of response moder-
ately correlated with the expression of TF protein (c =
0.501; p = 0.041), PAR2 mRNA (c = 0.618; p = 0.008)
and to PAR2 protein (c = 0.430; p = 0.085).
Comparison of TF release by the cell lines under resting
condition and following PAR2-activation
Under resting conditions the level of TF release as
microvesicles greatly varied between the cell lines exam-
ined with ASPC-1, HT-29 and NCI-H209 releasing high
levels of TF while SKOV-3 cells being restrained (Fig. 4).
The release of TF from the cells under resting condi-
tions did not correlate with any of the parameters mea-
sured. Using the data generated from the time-course
analysis (Fig. 3), microvesicles were isolated from the
conditioned media of activated cell, at the time-points of
maximal TF release for each cell line, and the TF activity
measured. At the point of maximal release, microvesicle-
associated TF activity was greatest in LoVo and ASPC-1
cells and lowest in MIA-PaCa-2 and ZR-751 cell lines
(Fig. 4). This maximal TF-release potential strongly cor-
related with TF mRNA expression (c = 0.717; p < 0.001)
and PAR2 mRNA expression (c = 0.770; p < 0.001), and
to a lesser extent correlated with cellular TF protein
levels (c = 0.507; p = 0.038) and the duration required for
achieving maximal release (c = 0.484; p = 0.049). The
maximum TF released also partially correlated with TF
release from resting cells (c = 0.483; p = 0.050) but not
the cell-surface TF activity (Table 1). Finally, the ability
to up-regulate TF release (not shown), expressed as the
increase in the TF release as a percentage of TF release
in non-activated cells, correlated with both PAR2 mRNA
expression (c = 0.601; p = 0.011) and PAR2 protein levels
(c = 0.714; p < 0.001) and was inversely correlated to the
level of TF release from non-activated cells (c = −0.453;
p = 0.053).
Comparison of microvesicle release by the cell lines
under resting condition and following PAR2-activation
Due to the nature of this investigation, the quantification
of the microvesicles was carried out according to the
functional properties of the microvesicles (i.e. phosphati-
dylserine content) rather that the physical quantities of
the microvesicles (number and size distribution). The
level of microvesicles release varied greatly between the
cell lines (Fig. 5) and the greatest increase in microvesi-
cle release was observed in CorL23, A375 and LS174T
cell lines. Neither the density of microvesicle released
after activation, nor the increase in the microvesicle
density correlated with any of the other parameters. Fur-
thermore, the release of microvesicles under resting condi-
tions only correlated weakly with the amount of cellular
PAR2 protein (c = 0.441; p = 0.100).
Discussion
The association between cancer and thrombosis has long
been established and many of the factors linking these
conditions have been characterised [1, 16, 45]. However,
parallel associations between procoagulant properties of
cancer cells and the induction of blood coagulation do not
appear to be sufficiently significant to permit the prognos-
tic determination of the risk of thrombosis [4, 6]. The abil-
ity of cancer cells to express high levels of TF is well
established [2] but the examination of the level of total
and surface TF antigen, or cell-surface TF activity does not
present a clear and definitive correlation with risk of clot
formation [5, 6, 19–21]. In addition, while there has been
a recent upsurge in studies examining the association of
TF-bearing microvesicles and incidence of thrombo-
embolism, correlations arising from these data have been
reported to be heterogeneous [14, 45]. It has been dem-
onstrated that released microvesicles are rapidly cleared
by cellular uptake in vitro and from the bloodstream in
vivo, with estimates ranging from minutes to a few
hours [33, 46–51]. Consequently, any TF released as
tumour-derived microvesicles may not remain within
the circulation for long enough to accumulate to levels
capable of promoting clot formation while concur-
rently, TF-bearing microvesicles may be present at
measurable levels at the time of sampling. One feature
of many cells is the ability to release TF as microvesi-
cles in bursts upon activation of the cell. Such bursts in
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TF release into the bloodstream may fluctuate in duration
and magnitude and may also vary in the length of time be-
fore the onset of the release of TF-bearing microvesicle
[16, 52, 53]. Therefore, in this study we examined the abil-
ity of seventeen cancer cell lines spanning various tissues
to release TF in response to PAR2 activation. We used
PAR2 activation as a stimulus for the study since 1) the re-
lease of TF-bearing microvesicles occurs in a much
shorter time than for example stimulation with TNFα [54]
and also, remained unaltered in the untreated control
cells. 2) PAR2 activation represents a more controlled acti-
vation of cells without influencing other pro-inflammatory
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Fig. 3 Time course of the microvesicle-associated TF activity released into the media by the cell lines. Cells (2 × 105) were seeded out in 6-well plates
and pre-adapted to respective serum-free medium. Microvesicle release was induced by incubation with PAR2-AP; SLIGRL; (20 μM). The released cell-
derived microvesicles were isolated by ultracentrifugation at intervals up to 90 min and resuspended in Tris-saline. Microvesicle-associated TF activity
was measured using the thrombin-generation assay, for each sample (n = 3)
Ettelaie et al. Thrombosis Journal  (2016) 14:2 Page 8 of 12
mechanisms within the cell as observed with LPS treat-
ment. Together, these advantages permit the analysis of
TF release without the influences arising from de novo
expression of various genes which may complicate the
analysis. Finally, 3) we hypothesise that the exposure of
tumour cells to bloodstream may induce low level gener-
ation of factor Xa and TF-factor VIIa complex allowing
for the activation of PAR2 on cancer cells, without sub-
stantial amounts of clot formation within the tumour cells’
immediate locality.
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Fig. 5 Analysis of minimal and maximal levels of released microvesicles by the cell lines. Cells (2 × 105) were seeded out in 6-well plates and
pre-adapted to respective serum-free medium. Microvesicle release was induced by incubation with PAR2-AP; SLIGRL; (20 μM) for the durations
determined in Fig. 3. The released cell-derived microvesicles were then isolated by ultracentrifugation at the interval with the maximum level of
microvesicle-associated TF activity (see Fig. 3). Samples of cells were also incubated for the same periods but without activation (resting) and
microvesicles isolated. The microvesicles were resuspended in Tris-saline and the density in each sample determined using the Zymuphen MP
assay kit. (n = 3; * = p < 0.05 vs. the respective non-activated sample)
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Fig. 4 Analysis of minimal and maximal levels of released microvesicle-associated TF activity by the cell lines. Cells (2 × 105) were seeded out in 6-well
plates and pre-adapted to respective serum-free medium. Microvesicle release was induced by incubation with PAR2-AP; SLIGRL; (20 μM). The released
cell-derived microvesicles were then isolated by ultracentrifugation prior to activation (resting), and at the interval with the maximum level of
microvesicle-associated TF activity (see Fig. 3). The microvesicles were resuspended in Tris-saline and TF activity in each sample was measured
using the thrombin-generation assay, in each sample. (n = 3; * = p < 0.05 vs. the respective non-activated sample) (N/T = Not tested)
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Activation of cells generally resulted in the upregula-
tion of TF release within 30–60 min but varied hugely in
magnitude in the cell lines tested. Interestingly, the
change in the rate of TF release in activated cells was
only moderately dependent on the rate of TF release
while under resting conditions, or the amount of TF
protein stored within the cells. Previously, we showed
that the suppression of TF expression in five cell lines
resulted in divergent rates of decline in the amount of
cellular TF [35]. This was attributed to the background
rate of TF release from these cells indicating that TF re-
serves were depleted at a faster rate when the amount of
microvesicle-associated TF was maintained by the cells.
In fact the percentage increase in the TF release follow-
ing activation appeared to be inversely correlated to the
ability of cells to release TF under resting conditions.
Therefore, the level of cellular TF protein stored within
the cells may be a function of the turnover of TF, deter-
mined by both the expression of TF mRNA and TF pro-
tein release from the cells and hence, only partly
correlates with TF mRNA expression. This also explains
the heterogeneous correlation between the level of circu-
lating TF containing microvesicles and the incidence of
thrombosis [14, 45] since this correlation may be positive
or negative, depending on whether the tumour cells are
activated at the time of sampling. In addition, a weak cor-
relation between cell surface TF activity and microvesicle-
associated TF activity was detected in resting cells. This is
also in agreement with the notion that TF is transferred to
the cell surface prior to release as microvesicle although,
the control of TF activity at the cell surface may strongly
be regulated by TF encryption [4]. In agreement with the
above hypothesis, the level of microvesicle-associated TF
during the short-term burst in TF release would be
dependent on the ability of cell to replenish TF reserves
through mRNA expression and therefore strongly corre-
lated with the TF mRNA expression levels. Furthermore,
the magnitude of TF release correlated strongly with the
PAR2 mRNA expression in the cells. Interestingly, the
level of TF mRNA expression also strongly correlated with
the expression of PAR2 mRNA but not PAR2 protein.
However, the turnover of PAR2 includes internalisation,
recycling and degradation which may alter the perceived
level of available PAR2 protein. The induction of TF ex-
pression following PAR2 activation has been shown previ-
ously [55]. Therefore, low level activation of PAR2 may
also contribute to the ability of cells to replenish TF re-
serves and enhance the cellular “TF-release potential”
through separate mechanisms involving the upregulation
of TF gene expression. However, the change in TF release,
as a percentage of the levels observed in resting cells ap-
pears to be related to PAR2 mRNA and PAR2 protein
levels. Perhaps this is not surprising in our experiments
since the cells were activated by incubation with PAR-
activating peptide. However, it is surprising that 1) the
strongest correlation was observed between TF release
and PAR2 mRNA expression and 2) some cell lines such a
ZR-75-1 did not respond proportionally to PAR2 activa-
tion. In contrast, the phosphorylation and the subsequent
release of TF is not dependent of PAR1 activation [24, 56].
Although, the release of microvesicles themselves may
occur upon activation of PAR1 and PAR2 by separate
mechanisms [57]. In our present study, we did not observe
a significant correlation between microvesicle release and
TF release, although in general a higher TF release was
often accompanied with moderate to high microvesicle re-
lease. Therefore, it is unlikely that PAR1 activation would
have any direct influence on TF release potential although
indirect mechanisms have not been ruled out. Addition-
ally, since glycosylation of PAR2 may alter its trafficking
and function, the patterns observed in Fig. 2 may hold fur-
ther clues to the "TF-release potential" property of the cell
lines and need further investigation.
Conclusion
Our cohort of cell lines used in this study was not suffi-
ciently large to merit the inference of attributes to par-
ticular types of cancer and as such, we have avoided
such speculation. However, more extensive studies of
these parameter may provide characteristic trends in dif-
ferent cancer types. In conclusion, this study is consist-
ent with previous reports and suggests that while PAR2
may maintain the level of TF expression [55] this does
not constitute a superior biomarker than measuring TF
itself. In contrast, the ability of cells to release TF as
cell-derived microvesicles may be upregulated rapidly
and significantly following the activation of PAR2.
Therefore, quantification of the levels of TF and PAR2
mRNA and possibly PAR2 protein, may prove to be a
means of determining the potential of cancer cells to re-
lease TF-containing microvesicles and constitute a more
accurate predictor of risk of thrombosis in vivo.
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